Treatment of Lichen Sclerosus

First-Line Treatment Protocol

The American Urological Association recommends clobetasol propionate 0.05% cream/ointment applied twice daily for 2-3 months, with gradual dose tapering after clinical improvement 1
The British Association of Dermatologists suggests that after clinical improvement, the dose should be tapered to minimize side effects while maintaining disease control, with a typical maintenance regimen involving decreasing to alternate days for 4 weeks, then twice weekly application 1, 4
Patients should be advised to avoid local irritants like strong soaps and moisturizers, and proper hand washing after application is essential to prevent medication spread to sensitive areas or partners 1

The British Association of Dermatologists recommends ultrapotent topical corticosteroids as superior to testosterone and progesterone treatments for female anogenital lichen sclerosus 1, 6
Asymptomatic patients with clinically active disease should still be treated, and surgery should be reserved only for malignancy and postinflammatory sequelae, not for uncomplicated LS 3, 6

The British Association of Dermatologists suggests that clobetasol propionate 0.05% has been documented as safe and effective in men, improving discomfort, skin tightness, and urinary flow 2, 6
Topical steroid treatment may reduce the need for circumcision, and for cases with structural changes due to scarring, surgical intervention may be necessary 2, 6

The American Academy of Pediatrics recommends ultrapotent topical corticosteroids as effective in children, but should be used with caution, and there is no evidence supporting the use of topical estrogens or testosterone in children 1, 2

For steroid-resistant cases, the British Association of Dermatologists recommends considering calcineurin inhibitors, though caution is advised due to potential increased risk of neoplasia, and systemic treatments should be reserved for severe, nonresponsive cases 2, 1, 4

The British Association of Dermatologists suggests that photodynamic therapy and cryotherapy may be beneficial in some cases, with cryotherapy providing symptom relief in 75% of patients with severe intractable itch 6

The American Urological Association recommends that all patients should be reviewed after the initial treatment period to assess response, and long-term follow-up in specialized clinics is unnecessary for uncomplicated, well-controlled disease 5, 3
Patients should be educated about the small but real risk of malignant transformation (<5%) and advised to report any suspicious lesions, and most patients with ongoing disease require approximately 30-60g of clobetasol propionate annually 3, 5